Stay updated on Pembrolizumab in Untreated Extensive SCLC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in Untreated Extensive SCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in Untreated Extensive SCLC Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    A sitewide NIH notice announces transition updates and says federal agencies are using “Super Intelligence” instead of “Artificial Intelligence.”
    Difference
    1%
    Check dated 2026-10-25T02:16:09.000Z thumbnail image
  2. Check
    13 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.1 to v3.7.2 on the 403 Forbidden page.
    Difference
    0.2%
    Check dated 2026-10-18T02:00:12.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    The footer revision number changed from v3.7.0 to v3.7.1; the page remains a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-11T02:37:30.000Z thumbnail image
  4. Check
    41 days ago
    Change Detected
    Summary
    The page now loads a 403 Forbidden error instead of the expected study details, indicating access to the record is blocked. The visible content shows a 403 message and header HTML, replacing the usual study information and navigation.
    Difference
    18%
    Check dated 2026-09-20T01:06:15.000Z thumbnail image
  5. Check
    62 days ago
    Change Detected
    Summary
    A funding note for 2014 NIH Grant/Contract was added and the page revision was updated to v3.6.6, with the previous revision v3.6.5 removed.
    Difference
    0.1%
    Check dated 2026-08-29T19:42:46.000Z thumbnail image
  6. Check
    84 days ago
    Change Detected
    Summary
    The page now displays a generic error screen indicating the requested content is temporarily unavailable, replacing the usual study record content. This reflects a site error rather than a substantive update to the study data.
    Difference
    17%
    Check dated 2026-08-08T10:13:26.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in Untreated Extensive SCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Untreated Extensive SCLC Clinical Trial page.